Ftse Mib
34.603,61
0,00%
DAX
18.726,36
0,00%
S&P 500
5.321,41
0,25%
NASDAQ
16.832,62
0,22%
Bitcoin
69.759,72
-0,53%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Athira Pharma Inc (ATHA) Athira Pharma Inc (ATHA) Notizie

ATHA

Athira Pharma (ATHA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATHA
DataOraFonteTitoloSimboloCompagnia
17/05/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHAAthira Pharma Inc
17/05/202423:00GlobeNewswire Inc.Athira Pharma Announces Proposed Settlement of Stockholder Derivative ActionNASDAQ:ATHAAthira Pharma Inc
15/05/202422:05GlobeNewswire Inc.Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
02/05/202413:00GlobeNewswire Inc.Athira Pharma to Participate in Upcoming May ConferencesNASDAQ:ATHAAthira Pharma Inc
15/04/202413:00GlobeNewswire Inc.Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerNASDAQ:ATHAAthira Pharma Inc
11/04/202413:00GlobeNewswire Inc.Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
03/04/202413:00GlobeNewswire Inc.Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:ATHAAthira Pharma Inc
08/03/202413:00GlobeNewswire Inc.Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International ConferenceNASDAQ:ATHAAthira Pharma Inc
22/02/202422:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATHAAthira Pharma Inc
22/02/202422:05GlobeNewswire Inc.Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
16/02/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATHAAthira Pharma Inc
16/02/202422:40Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ATHAAthira Pharma Inc
08/02/202422:02GlobeNewswire Inc.Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)NASDAQ:ATHAAthira Pharma Inc
08/01/202413:00GlobeNewswire Inc.Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business UpdateNASDAQ:ATHAAthira Pharma Inc
03/01/202413:00GlobeNewswire Inc.Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
12/12/202313:00GlobeNewswire Inc.Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy BodiesNASDAQ:ATHAAthira Pharma Inc
29/11/202313:00GlobeNewswire Inc.Athira Pharma to Participate in Sidoti December Small Cap Investor ConferenceNASDAQ:ATHAAthira Pharma Inc
28/11/202313:00GlobeNewswire Inc.Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MNDNASDAQ:ATHAAthira Pharma Inc
15/11/202314:15GlobeNewswire Inc.Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
09/11/202322:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATHAAthira Pharma Inc
09/11/202322:05GlobeNewswire Inc.Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
08/11/202313:00GlobeNewswire Inc.Athira Pharma to Participate in Jefferies London Healthcare ConferenceNASDAQ:ATHAAthira Pharma Inc
05/10/202322:30GlobeNewswire Inc.Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)NASDAQ:ATHAAthira Pharma Inc
28/09/202313:00GlobeNewswire Inc.Athira Pharma to Participate in Upcoming October ConferencesNASDAQ:ATHAAthira Pharma Inc
19/09/202313:00GlobeNewswire Inc.Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:ATHAAthira Pharma Inc
10/08/202322:05GlobeNewswire Inc.Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
17/07/202313:00GlobeNewswire Inc.Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
06/07/202313:00GlobeNewswire Inc.Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023NASDAQ:ATHAAthira Pharma Inc
09/06/202323:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATHAAthira Pharma Inc
31/05/202313:00GlobeNewswire Inc.Athira Pharma to Participate in Upcoming June ConferencesNASDAQ:ATHAAthira Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATHA

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network